Aurobindo Pharma had a satisfactory performance in the current quarter due to stable demand and pricing conditions across their portfolio and geographical regions. In Q4FY23, the company's revenue reached INR 64,730 mn, showing an 11.4% increase compared to the previous year and a 1.0% increase compared to the previous quarter.